EGRX Eagle Pharmaceuticals, Inc.

81.83
+2  (2%)
Previous Close 80.10
Open 80.65
Price To book 8.12
Market Cap 1.25B
Shares 15,227,000
Volume 229,425
Short Ratio 16.36
Av. Daily Volume 314,557

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date October 30, 2017.
Ready-to-dilute (RTD) Pemetrexed Injection
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
Rolling NDA filing initiated November 11, 2016. Announced completion January 23, 2017. Priority review requested.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Ryanodex
Malignant hyperthermia - cancer

Latest News

  1. Director of Eagle Pharmaceuticals Buys Shares
  2. EAGLE PHARMACEUTICALS, INC. Financials
  3. Eagle Pharma Cancer Drug Secures New Patents
  4. Eagle Pharmaceuticals Announces Three New Patents Issued for Bendeka
  5. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,
  6. Eagle Pharmaceuticals Appoints Richard A. Edlin to Board of Directors
  7. EAGLE PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
  8. New Strong Sell Stocks for March 6th
  9. Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017
  10. Eagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017
  11. Edited Transcript of EGRX earnings conference call or presentation 1-Mar-17 1:30pm GMT
  12. Q4 2016 Eagle Pharmaceuticals Inc Earnings Release - Before Market Open
  13. Eagle Pharmaceuticals posts 4Q profit
  14. Eagle Pharmaceuticals posts 4Q profit
  15. EAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
  16. Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results
  17. Eagle Pharmaceuticals’ Pemetrexed NDA Accepted for Filing by the FDA
  18. MedTech Stocks' Q4 Earnings on Mar 1: ICUI, GKOS & EGRX
  19. Eagle Pharmaceuticals Announces 11th Patent Issued for Bendeka
  20. Eagle Pharmaceuticals Announces New Patents Issued for Bendeka